US Stocks Mixed; Sea Shares Gain After Q3 Results - MSP Recovery (NASDAQ:MSPR), Outset Medical (NASDAQ:OM)

Market Overview - U.S. stocks exhibited mixed trading, with the Nasdaq Composite declining over 0.4% on Tuesday. The Dow increased by 0.13% to 47,430.01, while the S&P 500 fell by 0.15% to 6,823.18 [1] - Energy shares rose by 0.9%, whereas information technology stocks decreased by 0.7% [1] Company Performance - Sea Ltd (NYSE:SE) saw its shares rise approximately 4% after reporting fiscal Q3 2025 results, with revenue increasing by 38.3% year-on-year to $5.99 billion, surpassing analyst expectations of $5.65 billion. However, earnings per share were 59 cents, missing the consensus forecast of 77 cents [2] Commodity Market - In commodity trading, oil prices increased by 1.1% to $60.76, gold rose by 0.7% to $4,151.60, silver gained 1.4% to $51.030, while copper fell by 0.3% to $5.0915 [5] European Market - European shares experienced gains, with the eurozone's STOXX 600 rising by 0.8%, Spain's IBEX 35 Index up by 0.8%, London's FTSE 100 increasing by 0.8%, Germany's DAX 40 gaining 0.2%, and France's CAC 40 climbing by 0.9% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 down by 0.14%, Hong Kong's Hang Seng up by 0.18%, China's Shanghai Composite declining by 0.39%, and India's BSE Sensex rising by 0.40% [7] Notable Stock Movements - MSP Recovery Inc (NASDAQ:MSPR) shares surged 104% to $0.65 after a previous decline of 15%. Quoin Pharmaceuticals Ltd (NASDAQ:QNRX) shares increased by 51% to $12.47 following the announcement of achieving target loadings for proprietary delivery technologies. Surmodics Inc (NASDAQ:SRDX) shares rose by 50% to $41.08 after a court denied the FTC's bid to block an acquisition [9] - Conversely, Vor Biopharma Inc (NASDAQ:VOR) shares dropped 48% to $9.87 due to a public offering announcement, while Salarius Pharmaceuticals Inc (NASDAQ:SLRX) fell 50% to $1.00 after announcing a $7 million public offering. Outset Medical Inc (NASDAQ:OM) shares decreased by 42% to $7.04 following worse-than-expected Q3 results and a lowered FY25 sales guidance [9]